NEW YORK — Scott Gottlieb, the commissioner of the Food and Drug Administration, is a free-market proponent in a fervently anti-regulatory administration who is trying to lower drug prices by expanding the regulatory reach of the agency.
Speaking Wednesday at CNBC’s Healthy Returns conference, Gottlieb criticized branded drug companies, distributors, and pharmacy benefit managers for practices that reduce competition and restrict market access to generic drugs, including biosimilars.
The FDA cannot regulate drug prices, but the agency is enacting new policies to speed the testing and approval of generic drugs, which in turn, should lead to lower overall drug prices.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
